Multiple-dose crossover study of once-daily inhaled aclidinium bromide 200 µg (morning vs evening) in moderate to severe COPD

Phase 2, randomised, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Almirall. Primary endpoints: Bronchodilator response at steady state (time-of-dosing effect) and Safety and tolerability of multiple doses of aclidinium bromide. Started Aug 2007; status: completed.